Lonsurf Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com
Dallas, TX (PRWEB) December 27, 2014 -- The report “Lonsurf (Colorectal Cancer) – Forecast and Market Analysis to 2023” focuses on the current treatment landscape, unmet needs, current pipeline and commercial opportunities in the colorectal cancer market. Taiho Pharmaceutical’s Lonsurf (TAS-102) is an oral nucleoside antitumor drug which launched in 2014 for the treatment of chemotherapy-refractive metastatic CRC in Japan. In May 2014, Taiho Pharmaceutical announced that the Phase III RECOURSE trial met its primary outcome of OS and that the company is preparing for regulatory submission in the US and Europe. In October 2014, Taiho announced that Lonsurf has received FDA Fast-Track designation and had initiated rolling NDA submission. This positive outcome follows the announcement in March 2014 that Lonsurf had gained regulatory approval for the treatment of recurrent unresectable locally advanced or metastatic CRC in Japan based on Phase II data. Complete Report is Available at http://www.rnrmarketresearch.com/lonsurf-colorectal-cancer-forecast-and-market-analysis-to-2023-market-report.html.
Lonsurf is an anti-cancer drug which is prescribed for treating colorectal cancer. The drug is administered orally and it is a combination of trifluridine (FTD) and tipiracil hydrochloride (TPI). Trifluridine which is an antineoplastic nucleoside analog is incorporated directly into DNA, thereby interfering with the function of DNA. Lonsurf was approved to be sold in Japan by the Ministry of Health, Labour and Welfare in March 2014. In the US, Europe, and Canada, the drug is currently in phase 3 trials. Lonsurf is administered twice a day, for five days. Side effects of the drug might include loss of appetite, diarrhea, vomiting, nausea and fatigue.
Scope
• Overview of Colorectal Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Lonsurf including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Lonsurf for the top eight countries from 2013 to 2023.
• Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.
Order a Purchase copy of report at http://www.rnrmarketresearch.com/contacts/purchase?rname=251701.
Table of Contents
1 Table of Contents
1.1 List of Tables
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Clinical Staging
3.3 Symptoms
4 Disease Management
4.1 Diagnosis and Treatment Overview
4.1.1 Screening and Diagnosis
4.1.2 Treatment Guidelines and Leading Prescribed Drugs
4.1.3 Clinical Practice
5 Competitive Assessment
5.1 Overview
6 Lonsurf (TAS-102)
6.1 Overview
6.2 Efficacy
6.3 Safety
6.4 SWOT Analysis
6.5 Forecast
7 Appendix
7.1 Bibliography
7.2 Abbreviations
7.3 Methodology
7.4 Forecasting Methodology
7.4.1 Diagnosed Colorectal Cancer Patients
7.4.2 Percent Drug-Treated Patients
7.4.3 General Pricing Assumptions
7.4.4 Average Body Weight and Surface Area Across the 8MM
7.4.5 Individual Drug Assumptions
7.4.6 Generic Erosion
7.5 Primary Research - KOLs Interviewed for this Report
7.6 Primary Research - Prescriber Survey
7.7 About the Authors
7.7.1 Analyst
7.7.2 Global Head of Healthcare
7.8 About GlobalData
7.9 Disclaimer
List of Tables
Table 1: TNM and Staging Classification System for CRC
Table 2: Symptoms of Colorectal Cancer
Table 3: Treatment Guidelines for CRC
Table 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the Global Markets, 2013
Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the Global Markets, 2013
Table 6: Leading Treatments for CRC, 2014
Table 7: Product Profile - Lonsurf
Table 8: Lonsurf SWOT Analysis, 2014
Table 9: Global Sales Forecasts ($m) for Lonsurf (TAS-102), 2013-2023
Table 10: Average Body Weight and Surface Area Across the 8MM
Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
Explore more reports on Cancer Drugs industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/cancer-drugs.
About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
Ritesh Tiwari, Deep Research Reports, http://www.deepresearchreports.com/, +1 (888) 391-5441, [email protected]
Share this article